|1.||Schenone, Silvia: 9 articles (01/2015 - 03/2004)|
|2.||Botta, Maurizio: 9 articles (01/2015 - 03/2004)|
|3.||Brullo, Chiara: 5 articles (01/2015 - 03/2004)|
|4.||Maga, Giovanni: 5 articles (01/2015 - 03/2007)|
|5.||Gangjee, Aleem: 5 articles (06/2013 - 11/2003)|
|6.||Naldini, Antonella: 5 articles (04/2011 - 03/2004)|
|7.||Carraro, Fabio: 5 articles (04/2011 - 03/2004)|
|8.||Radi, Marco: 4 articles (01/2015 - 01/2009)|
|9.||Manetti, Fabrizio: 4 articles (01/2009 - 03/2004)|
|10.||Serebruany, Victor L: 3 articles (09/2015 - 01/2010)|
01/01/2013 - "A variety of novel thieno[3,2-d]pyrimidines with different decorating functional groups were synthesized as a part of a study aiming to enrich the arsenal of chemotherapeutic agents for the treatment of cancer. "
03/01/1995 - "Thus, we present here a new, feasible and reproducible animal model, excellently suited to in vivo and in vitro studies of fluorinated pyrimidines and solid tumor growth."
05/01/1989 - "Emphasis is placed on the effects and the mechanism of action of halogenated pyrimidines, since recent clinical trials indicated the potential importance of these compounds in the treatment of certain types of human tumors. "
01/01/1985 - "Studies on 18F-labeled pyrimidines III. Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice."
09/01/1964 - "STUDIES ON THE MECHANISM OF HUMAN TUMOR RESISTANCE TO THE FLUORINATED PYRIMIDINES."
|2.||Colorectal Neoplasms (Colorectal Cancer)
11/01/1984 - "The improved therapeutic index of the fluorinated pyrimidines when given via continuous infusion must be explored in randomized controlled studies using malignancies other than colorectal cancer. "
04/01/1989 - "A preliminary description of ongoing studies of the tissue concentrations of FUra and metabolites in human colorectal carcinoma and in adjacent normal bowel after rapid injection and after 24-hour infusion of radiolabelled pharmacologically active doses of FUra is included as one approach to learning more about the cellular pharmacology of fluorinated pyrimidines."
01/01/2012 - "The increase in the therapeutic arsenal in the last 20 years, has given rise to changes in treating colorectal cancer (CRC) with only pyrimidines to combine several cytotoxic drugs. "
02/01/2004 - "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability. "
01/01/2001 - "In that context, and recognizing the limitations of the techniques available, an attempt will be made to address the question of the economic impact of oral fluorinated pyrimidines on the management of colorectal cancer."
|3.||Astrocytoma (Pilocytic Astrocytoma)
12/01/1996 - "Comment on "survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II Study"."
12/01/1996 - "Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study."
04/28/2011 - "Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study."
03/13/2008 - "Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines."
03/01/2007 - "Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells."
01/01/1970 - "[Mode of action of alkylated pyrimidines in Friend virus leukemia]."
03/01/2007 - "A series of pyrazolo[3,4-d]pyrimidines, previously found to be Src inhibitors, was tested for their ability to inhibit proliferation of three Bcr-Abl-positive human leukemia cell lines (K-562, KU-812, and MEG-01), on the basis of the experimental evidence that various Src inhibitors are also active against Bcr-Abl kinase (the so called dual Src/Abl inhibitors). "
10/01/1998 - "We evaluated whether we could similarly deliver halogenated pyrimidines to experimental intracranial human malignant glioma. "
05/01/1997 - "The potential of halogenated pyrimidines for the radiosensitization of human malignant gliomas remains unrealized. "
08/01/1991 - "Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited."
02/01/1992 - "The clinical response of both the high grade glioma and head and neck tumor patients indicate that the IdUrd replacement and labeling data may provide some important predictive information with regard to the successful use of the halogenated pyrimidines in clinical radiation trials."
06/01/1999 - "The data suggest that DNA damage induced by halogenated pyrimidines may not involve interstrand cross-links and that these agents may be useful in the treatment of glioma in combination with alkylating agents."
|7.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|9.||Histamine (Histamine Dihydrochloride)
|10.||DCMP Deaminase (Deoxycytidylate Deaminase)
|2.||Heterologous Transplantation (Xenotransplantation)